Supplemental Evidence and Data Request on Healthcare Industry Waste and Lifecycle Assessment, 67294-67295 [2023-21481]
Download as PDF
<![CDATA[
67294
Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices
EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN—Continued
Number of
respondents
Form name
Total
burden
hours
Average
hourly wage
rate
Total cost
burden
Office-based Providers Event Form ................................................................................
Separately Billing Doctors (SBD) Event Form ................................................................
Hospitals & HMOs (Hospital Event Form ........................................................................
Institutions (non-hospital) Event Form .............................................................................
Pharmacies Event Form ..................................................................................................
Subtotal for the MEPS–MPC ...........................................................................................
14,950
12,690
8,302
118
9,079
100,783
3,214
888
3,113
8
17,068
29,111
** 19.84
** 19.84
** 19.84
** 19.84
*** 19.35
....................
63,766
17,618
61,762
159
330,266
569,200
Grand Total ...............................................................................................................
142,383
77,067
....................
1,979,436
* Mean hourly wage for All Occupations (00–0000).
** Mean hourly wage for Medical Secretaries (43–6013).
*** Mean hourly wage for Pharmacy Technicians (29–2052).
Occupational Employment Statistics, May 2022 National Occupational Employment and Wage Estimates United States, U.S. Department of
Labor, Bureau of Labor Statistics.
Request for Comments
Dated: September 26, 2023.
Marquita Cullom,
Associate Director.
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Healthcare Industry Waste and Lifecycle
Assessment, which is currently being
conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program.
Access to published and unpublished
pertinent scientific information will
improve the quality of this review.
DATES: Submission Deadline on or
before October 30, 2023.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
[FR Doc. 2023–21473 Filed 9–28–23; 8:45 am]
FOR FURTHER INFORMATION CONTACT:
BILLING CODE 4160–90–P
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Healthcare Industry Waste
and Lifecycle Assessment. AHRQ is
conducting this review pursuant to
section 902 of the Public Health Service
Act, 42 U.S.C. 299a.
The EPC Program is dedicated to
identifying as many studies as possible
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
lotter on DSK11XQN23PROD with NOTICES1
Request for supplemental
evidence and data submissions.
ACTION:
In accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3520,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) whether the
proposed collection of information is
necessary for the proper performance of
AHRQ’s health care research and health
care information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Healthcare Industry Waste
and Lifecycle Assessment
Agency for Healthcare Research
and Quality (AHRQ), HHS.
AGENCY:
VerDate Sep<11>2014
21:46 Sep 28, 2023
Jkt 259001
SUMMARY:
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Healthcare Industry
Waste and Lifecycle Assessment. The
entire research protocol is available
online at: https://effectivehealthcare.
ahrq.gov/products/lifecycle-assessment.
This is to notify the public that the
EPC Program would find the following
information on Healthcare Industry
Waste and Lifecycle Assessment helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
methodology, indication and diagnosis,
proper use instructions, inclusion and
exclusion criteria, and primary and
secondary outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this topic and an index
E:\FR\FM\29SEN1.SGM
29SEN1
Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices
outlining the relevant information in
each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on topics not included in
the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://www.effectivehealthcare.
ahrq.gov/email-updates.
The review will answer the following
questions. This information is provided
as background. AHRQ is not requesting
that the public provide answers to these
questions.
Guiding Questions (GQ)
GQ1. Frameworks for Life Cycle
Assessment (LCA)
• What LCA frameworks have been
developed or adapted for healthcare
settings, products, and procedures?
i. What data sources, measures/
indicators, and methods are used to
inform these frameworks?
ii. Which components of the
frameworks are thought to have the
greatest association with carbon
footprint?
iii. What limitations of these
frameworks have been described?
67295
GQ2. Studies of LCA
• How are LCAs applied in healthcare
research?
i. What topic areas have been studied
and for what settings?
ii. What data sources, measures/
indicators, and methods were used in
the analysis?
iii. What outcomes have been studied,
and what were the findings?
iv. What were cited limitations of the
research?
GQ3. Gaps in the Knowledge and Future
Research Needs
• Are there frameworks that are being
developed or have been developed but
not yet implemented?
• What are possible areas of future
research?
CRITERIA FOR INCLUSION/EXCLUSION OF STUDIES IN THE REVIEW
Domain
Inclusion
Exclusion
Population ........
• GQ1: Publications that include a figure or detailed description of a life cycle assessment framework.
• GQ2: Publications that describe the methods and results of
a life cycle assessment study.
• GQ3: Registered research of life cycle framework development or assessment.
Life cycle assessments that address either scope 1, scope 2,
scope 3 emissions. Scope 1: Direct emissions (facilities,
anesthetics, fleet and leased vehicles), Scope 2: Indirect
emissions (electricity, stream). Scope 3: Other indirect
emissions (food and catering, business services, medical
devices, medicines, water, metered-dose inhalers, energy
[well-to-tank], business travel [public transit, gray fleet],
staff commuting, manufacturing [products, chemicals,
gases], waste, information technology, Health Care Organization (HCO) investments, construction, and freight transport).
• GQ1: Frameworks for life cycle assessments, including
logic
models,
analytic
frameworks,
or
other
conceptualization.
• GQ2: Published life cycle assessments, life cycle assessments do not need to meet ISO (International Organization
for Standardization) 14040 standards but need to describe
a goal, scope, and boundaries; assessment can describe
partials or full cradle to grave cycles.
• GQ3: Ongoing research, development of frameworks and
assessments.
• Healthcare: healthcare delivery organizations, health insurance, or manufacturers/suppliers that directly contribute to
the delivery of healthcare (e.g., supply of personal protective equipment) including scope 1, scope 2, and scope 3
emissions.
• Information published in English-language journal manuscripts, trial records, and gray literature in the public domain from the outlined sources.
• Publications citing existing frameworks without further conceptual contribution to the framework and publications describing only the need or future plans of conducting a life
cycle assessment.
Concept ............
Context .............
lotter on DSK11XQN23PROD with NOTICES1
Other limiter ......
Abbreviations: GQ guiding questions;
HCO health care organization; ISO
International Standards Organization.
• Frameworks, assessments, ongoing research not including
life cycle assessments.
• Studies in contexts not specific to healthcare.
• Data reported in abbreviated format (e.g., conference abstracts) will be excluded; systematic reviews will be retained for reference mining.
Dated: September 26, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023–21481 Filed 9–28–23; 8:45 am]
BILLING CODE 4160–90–P
VerDate Sep<11>2014
21:46 Sep 28, 2023
Jkt 259001
PO 00000
Frm 00071
Fmt 4703
Sfmt 9990
E:\FR\FM\29SEN1.SGM
29SEN1
]]>Agencies
[Federal Register Volume 88, Number 188 (Friday, September 29, 2023)]
[Notices]
[Pages 67294-67295]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21481]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on Healthcare Industry
Waste and Lifecycle Assessment
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submissions.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on Healthcare
Industry Waste and Lifecycle Assessment, which is currently being
conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program.
Access to published and unpublished pertinent scientific information
will improve the quality of this review.
DATES: Submission Deadline on or before October 30, 2023.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement,
Agency for Healthcare Research and Quality, ATTN: EPC SEADs
Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.): Center for Evidence and
Practice Improvement, Agency for Healthcare Research and Quality, ATTN:
EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for Healthcare Industry
Waste and Lifecycle Assessment. AHRQ is conducting this review pursuant
to section 902 of the Public Health Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Healthcare Industry Waste and Lifecycle Assessment. The
entire research protocol is available online at: https://effectivehealthcare.ahrq.gov/products/lifecycle-assessment.
This is to notify the public that the EPC Program would find the
following information on Healthcare Industry Waste and Lifecycle
Assessment helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this topic. In the list, please indicate whether results
are available on ClinicalTrials.gov along with the ClinicalTrials.gov
trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a summary, including the following elements, if
relevant: study number, study period, design, methodology, indication
and diagnosis, proper use instructions, inclusion and exclusion
criteria, primary and secondary outcomes, baseline characteristics,
number of patients screened/eligible/enrolled/lost to follow-up/
withdrawn/analyzed, effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including, if relevant, a study number, the
study period, design, methodology, indication and diagnosis, proper use
instructions, inclusion and exclusion criteria, and primary and
secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this topic and an index
[[Page 67295]]
outlining the relevant information in each submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on topics not included
in the review cannot be used by the EPC Program. This is a voluntary
request for information, and all costs for complying with this request
must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: https://www.effectivehealthcare.ahrq.gov/email-updates.
The review will answer the following questions. This information is
provided as background. AHRQ is not requesting that the public provide
answers to these questions.
Guiding Questions (GQ)
GQ1. Frameworks for Life Cycle Assessment (LCA)
What LCA frameworks have been developed or adapted for
healthcare settings, products, and procedures?
i. What data sources, measures/indicators, and methods are used to
inform these frameworks?
ii. Which components of the frameworks are thought to have the
greatest association with carbon footprint?
iii. What limitations of these frameworks have been described?
GQ2. Studies of LCA
How are LCAs applied in healthcare research?
i. What topic areas have been studied and for what settings?
ii. What data sources, measures/indicators, and methods were used
in the analysis?
iii. What outcomes have been studied, and what were the findings?
iv. What were cited limitations of the research?
GQ3. Gaps in the Knowledge and Future Research Needs
Are there frameworks that are being developed or have been
developed but not yet implemented?
What are possible areas of future research?
Criteria for Inclusion/Exclusion of Studies in the Review
------------------------------------------------------------------------
Domain Inclusion Exclusion
------------------------------------------------------------------------
Population.................. GQ1:
Publications that Publications citing
include a figure or existing frameworks
detailed without further
description of a conceptual
life cycle contribution to the
assessment framework and
framework. publications
GQ2: describing only the
Publications that need or future
describe the plans of conducting
methods and results a life cycle
of a life cycle assessment.
assessment study.
GQ3:
Registered research
of life cycle
framework
development or
assessment.
Concept..................... Life cycle Frameworks,
assessments that assessments,
address either ongoing research
scope 1, scope 2, not including life
scope 3 emissions. cycle assessments.
Scope 1: Direct
emissions
(facilities,
anesthetics, fleet
and leased
vehicles), Scope 2:
Indirect emissions
(electricity,
stream). Scope 3:
Other indirect
emissions (food and
catering, business
services, medical
devices, medicines,
water, metered-dose
inhalers, energy
[well-to-tank],
business travel
[public transit,
gray fleet], staff
commuting,
manufacturing
[products,
chemicals, gases],
waste, information
technology, Health
Care Organization
(HCO) investments,
construction, and
freight transport).
GQ1:
Frameworks for life
cycle assessments,
including logic
models, analytic
frameworks, or
other
conceptualization.
GQ2:
Published life
cycle assessments,
life cycle
assessments do not
need to meet ISO
(International
Organization for
Standardization)
14040 standards but
need to describe a
goal, scope, and
boundaries;
assessment can
describe partials
or full cradle to
grave cycles.
GQ3:
Ongoing research,
development of
frameworks and
assessments.
Context..................... Healthcare: Studies in
healthcare delivery contexts not
organizations, specific to
health insurance, healthcare.
or manufacturers/
suppliers that
directly contribute
to the delivery of
healthcare (e.g.,
supply of personal
protective
equipment)
including scope 1,
scope 2, and scope
3 emissions.
Other limiter............... Information Data
published in reported in
English-language abbreviated format
journal (e.g., conference
manuscripts, trial abstracts) will be
records, and gray excluded;
literature in the systematic reviews
public domain from will be retained
the outlined for reference
sources. mining.
------------------------------------------------------------------------
Abbreviations: GQ guiding questions; HCO health care organization;
ISO International Standards Organization.
Dated: September 26, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-21481 Filed 9-28-23; 8:45 am]
BILLING CODE 4160-90-P
